Anticoagulation and Thrombolytic Therapy

摘要: Although thrombolytic agents have been available for over 10 years and demonstrated safety efficacy in an increasing number of clinical conditions involving thrombotic phenomena, their general acceptance as first-line therapeutic medical management has slow. Much the reluctance to use these drugs is based on associated incidence hemorrhagic complications, which several-fold greater than with conventional anticoagulants. With introduction second-generation agents, made possible through successes recombinant DNA technology chemical modifications previously compounds, increased fibrin specificity achieved translated into safety. These results will likely improve innovative regimens using dose or multiple combined synergy are developed. An appreciation basic coagulation pharmacology anticoagulants necessary maximize benefits currently medications, develop new treatment strategies, minimize potential complications.